Article Text
PDFLetter
EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial
Statistics from Altmetric.com
Footnotes
-
Contributors All authors contributed to the conception and design or analysis and interpretation of data, drafting the article or revising it critically for important intellectual content and final approval of the version to be published.
-
Competing interests None.
-
Patient consent Obtained.
-
Ethics approval Ethics committee of the University Medical Center Groningen.
-
Provenance and peer review Not commissioned; externally peer reviewed.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions